Research Methodology and Study Design Philosophy

The Foundation's methodological philosophy is straightforward: apply the established standards of clinical research to every study, select the design that best answers the question at hand, and pre-specify how outcomes will be measured and analyzed. The Foundation does not favor any particular design in the abstract. It favors the design that is scientifically appropriate, ethically sound, and operationally feasible for the specific question.

Standards and Compliance

Studies are intended to be conducted in accordance with the following standards, adapted to the design and setting of each study.

• ICH Good Clinical Practice principles, providing the international benchmark for the design, conduct, recording, and reporting of clinical studies.

• Ethical standards consistent with the Declaration of Helsinki and applicable national ethical guidelines, including the National Ethical Guidelines for Biomedical and Health Research of the Indian Council of Medical Research for studies conducted in India.

• Applicable regulations in each jurisdiction, including, for India, the New Drugs and Clinical Trials Rules, 2019, and relevant guidance from the Central Drugs Standard Control Organisation and the Ministry of AYUSH, together with registration on the Clinical Trials Registry of India.

• Data quality standards covering source data verification, data provenance, and traceability appropriate to each data source.

• Quality management systems, including risk-based approaches to quality and documented standard operating procedures.

Designs in Scope

The program may draw on pragmatic clinical trials, Real-World Evidence studies, prospective registries, observational studies, and multi-center research programs, as described earlier in this document. The selection among these, and the detailed features of any protocol, are not predetermined. No final study designs have been fixed. Each will be developed by the relevant scientific and clinical experts, reviewed by an ethics committee or institutional review board, and registered as required before initiation.

Digital Health and Analytics

Contemporary clinical research increasingly relies on digital infrastructure to improve data quality, reduce burden on participants and sites, and support timely oversight. The Foundation anticipates the considered use of the following capabilities, subject to validation, data protection requirements, and the needs of each protocol.

• Electronic Data Capture for structured, auditable collection of study data.

• Electronic Patient-Reported Outcomes for direct, timestamped capture of participant-reported measures.

• Patient Portals to support communication, scheduling, and access to study information.

• Telemedicine Follow-Up to extend reach and reduce travel burden where clinically appropriate.

• Remote Monitoring of participants and of data quality between site visits.

• Wearables and connected devices for objective, continuous measurement.

• Digital Biomarkers derived from validated digital signals.

• Artificial Intelligence-Assisted Analytics to support data quality checks, signal detection, and analysis, applied transparently and with appropriate validation and human oversight.

• Risk-Based Monitoring to direct oversight toward the data and processes that matter most for participant safety and data integrity.

Any use of these tools will be documented, validated for its intended purpose, and applied in accordance with data protection and privacy requirements. Analytical methods, including any use of artificial intelligence, will be described transparently and will not substitute for qualified scientific and clinical judgment.

Patient Safety and Ethical Oversight

The safety, rights, and welfare of participants take precedence over every other consideration in the conduct of research. The Foundation's studies are designed so that ethical oversight is independent, informed consent is meaningful, and safety is monitored throughout. The elements below describe the safeguards that would apply, adapted to the design and risk profile of each study.

• Informed Consent. Participation is voluntary and based on clear information about the study, its purpose, its procedures, and any foreseeable risks, provided in a language and format the participant understands, with the right to withdraw at any time without penalty.

• Ethics Committees and Institutional Review Boards. Studies require review and approval by a properly constituted ethics committee or institutional review board before initiation, with continuing oversight during conduct.

• Participant Rights. Participants retain the right to information, to ask questions, to decline or discontinue participation, and to receive care that is not compromised by their decision.

• Privacy Protections and Data Security. Personal data are handled in accordance with applicable data protection laws, using access controls, encryption where appropriate, and defined retention practices.

• Participant Confidentiality. Data are de-identified or pseudonymized where feasible, and identifying information is restricted to authorized personnel.

• Adverse Event Reporting. Adverse events are recorded and reported in accordance with applicable requirements and timelines, with serious events subject to expedited processes.

• Safety Monitoring. Accumulating safety data are reviewed on a defined schedule, with an independent data review function engaged where the design warrants it.

• Participant Welfare. The overall design gives priority to minimizing burden and risk and to ensuring that participation is compatible with good clinical care.